Gavin P Reynolds

List of Publications by Year
in descending order

352 papers	20,247 citations	7551 77 h-index	13338 130 g-index
359 all docs	359 docs citations	359 times ranked	13073 citing authors

#	Article	IF	Citations
1	Subchronic PCP effects on DNA methylation and protein expression of NMDA receptor subunit genes in the prefrontal cortex and hippocampus of female rats. Journal of Psychopharmacology, 2022, 36, 238-244.	2.0	4
2	The neurochemical pathology of schizophrenia: post-mortem studies from dopamine to parvalbumin. Journal of Neural Transmission, 2022, 129, 643-647.	1.4	6
3	Early-life stress effects on BDNF DNA methylation in first-episode psychosis and in rats reared in isolation. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 108, 110188.	2.5	22
4	Schizophrenia, Depressive Symptoms, and Antipsychotic Drug Treatment. International Journal of Neuropsychopharmacology, 2021, 24, 253-255.	1.0	4
5	Changes ofBDNFexon IV DNA methylationÂare associated with methamphetamine dependence. Epigenomics, 2021, 13, 953-965.	1.0	11
6	Early life trauma, DNA methylation and mental illness. Epigenomics, 2021, 13, 825-827.	1.0	3
7	The relationship of childhood trauma and DNA methylation of NMDA receptor genes in first-episode schizophrenia. Epigenomics, 2021, 13, 927-937.	1.0	5
8	The Etiology of Metabolic Disturbances in Schizophrenia: Drugs, Genes, and Environment. International Journal of Neuropsychopharmacology, 2021, 24, 854-855.	1.0	2
9	High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?. Journal of Psychopharmacology, 2021, 35, 1030-1036.	2.0	6
10	Editorial: Pharmacogenomics and psychiatric disease. Neuroscience Letters, 2020, 726, 134602.	1.0	0
11	Uric Acid and High-Density Lipoprotein Cholesterol Are Differently Associated with Alzheimerâ€™s Disease and Vascular Dementia. Journal of Alzheimer's Disease, 2020, 73, 1125-1131.	1.2	8
12	Agricultural work and reduced circulating uric acid are both associated with initial hospital admission for Parkinsonâ€™s disease. Journal of Neural Transmission, 2020, 127, 779-783.	1.4	3
13	S8. GRIN1 PROMOTER METHYLATION CHANGES IN BLOOD OF EARLY-ONSET PSYCHOTIC PATIENTS AND UNAFFECTED SIBLINGS WITH CHILDHOOD TRAUMA. Schizophrenia Bulletin, 2020, 46, S32-S33.	2.3	0
14	Circulating microRNA changes in patients with impaired glucose regulation. Adipocyte, 2020, 9, 443-453.	1.3	9
15	Epigenetic-mediated N-methyl-D-aspartate receptor changes in the brain of isolated reared rats. Epigenomics, 2020, 12, 1983-1997.	1.0	8
16	CACNA1C methylation: association with cortisol, perceived stress, rs1006737 and childhood trauma in males. Epigenomics, 2020, 12, 1739-1749.	1.0	2
17	Antipsychotics, Weight Gain and Metabolic Risk. , 2020, , 619-619.		0
18	M9. RATS REARED IN SOCIAL ISOLATION INDUCES EPIGENETIC MODIFICATIONS IN THE NMDA RECEPTOR SUBUNITS. Schizophrenia Bulletin, 2020, 46, S136-S136.	2.3	0

#	Article	IF	Citations
19	Functional pharmacogenetics of serotonin receptors in psychiatric drug action. Handbook of Behavioral Neuroscience, 2020, 31, 941-957.	0.7	2
20	Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia. Journal of Clinical Psychiatry, 2020, 81, .	1.1	26
21	M210. GRIN2B METHYLATION IS RELATED TO PANSS EXCITED COMPONENT (PANSS-EC) IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2020, 46, S216-S216.	2.3	0
22	Adjunctive Lurasidone Suppresses Food Intake and Weight Gain Associated with Olanzapine Administration in Rats. Clinical Psychopharmacology and Neuroscience, 2019, 17, 314-317.	0.9	6
23	Interaction Between Variations in Dopamine D2 and Serotonin 2A Receptor is Associated with Short-Term Response to Antipsychotics in Schizophrenia. Neuroscience Bulletin, 2019, 35, 1102-1105.	1.5	2
24	Neuromyelitis optica spectrum disorder in three generations of a Chinese family. Multiple Sclerosis and Related Disorders, 2019, 32, 94-96.	0.9	3
25	GRIN2B promoter methylation deficits in early-onset schizophrenia and its association with cognitive function. Epigenomics, 2019, 11, 401-410.	1.0	34
26	Parvalbumin Promoter Methylation Altered in Major Depressive Disorder. International Journal of Medical Sciences, 2019, 16, 1207-1214.	1.1	12
27	Association study of the functional Catechol-O-Methyltranferase (COMT) Val¹⁵⁸Met polymorphism on executive cognitive function in a Thai sample. International Journal of Medical Sciences, 2019, 16, 1461-1465.	1.1	6
28	Association of SLC1A2 and SLC17A7 polymorphisms with major depressive disorder in a Thai population. Asian Biomedicine, 2019, 12, 131-138.	0.2	1
29	Lower uric acid is associated with poor short-term outcome and a higher frequency of posterior arterial involvement in ischemic stroke. Neurological Sciences, 2018, 39, 1117-1119.	0.9	11
30	Parvalbumin promoter hypermethylation in postmortem brain in schizophrenia. Epigenomics, 2018, 10, 519-524.	1.0	32
31	Genetic variation ofGRIA3gene is associated with vulnerability to methamphetamine dependence and its associated psychosis. Journal of Psychopharmacology, 2018, 32, 309-315.	2.0	11
32	S14. DNA METHYLATION CHANGES IN GABAERGIC AND GLUTAMATERGIC MARKERS IN EARLY SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S329-S329.	2.3	1
33	Development and evaluation of a dimensionless mechanistic pan coating model for the prediction of coated tablet appearance. International Journal of Pharmaceutics, 2017, 528, 180-201.	2.6	20
34	Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria. Therapeutic Advances in Psychopharmacology, 2017, 7, 1-14.	1.2	20
35	Association of polymorphisms in GAD1 and GAD2 genes with methamphetamine dependence. Pharmacogenomics, 2017, 18, 17-22.	0.6	7
36	Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment. Journal of Psychopharmacology, 2017, 31, 1430-1436.	2.0	47

#	Article	IF	Citations
37	Increased DNA methylation in the parvalbumin gene promoter is associated with methamphetamine dependence. Pharmacogenomics, 2017, 18, 1317-1322.	0.6	12
38	DAT1methylation is associated with methylphenidate response on oppositional and hyperactive-impulsive symptoms in children and adolescents with ADHD. World Journal of Biological Psychiatry, 2017, 18, 291-299.	1.3	44
39	Association of brainâ€derived neurotrophic factor valine to methionine polymorphism with sexual dysfunction following selective serotonin reuptake inhibitor treatment in female patients with major depressive disorder. Asia-Pacific Psychiatry, 2016, 8, 260-268.	1.2	1
40	Does elevated peripheral benzodiazepine receptor gene expression relate to cognitive deficits in methamphetamine dependence?. Human Psychopharmacology, 2016, 31, 243-246.	0.7	4
41	Blood oxygen level-dependent signals via fMRI in the mood-regulating circuit using two animal models of depression are reversed by chronic escitalopram treatment. Behavioural Brain Research, 2016, 311, 210-218.	1.2	19
42	Effect of Methamphetamine Exposure on Expression of Calcium Binding Proteins in Rat Frontal Cortex and Hippocampus. Neurotoxicity Research, 2016, 30, 427-433.	1.3	15
43	BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. Journal of Psychopharmacology, 2016, 30, 717-748.	2.0	200
44	Concurrent Risperidone Administration Attenuates the Development of Locomotor Sensitization Following Sub-Chronic Phencyclidine in Rats. Pharmacopsychiatry, 2016, 49, 62-65.	1.7	2
45	Subchronic administration of phencyclidine produces hypermethylation in the parvalbumin gene promoter in rat brain. Epigenomics, 2016, 8, 1179-1183.	1.0	22
46	TPH-2 Polymorphisms Interact with Early Life Stress to Influence Response to Treatment with Antidepressant Drugs. International Journal of Neuropsychopharmacology, 2016, 19, pyw070.	1.0	23
47	Modelling the cognitive and neuropathological features of schizophrenia with phencyclidine. Journal of Psychopharmacology, 2016, 30, 1141-1144.	2.0	28
48	Does DNA methylation influence the effects of psychiatric drugs?. Epigenomics, 2016, 8, 309-312.	1.0	15
49	BDNF (Val66Met) genetic polymorphism is associated with vulnerability for methamphetamine dependence. Pharmacogenomics, 2015, 16, 1541-1545.	0.6	27
50	Analysis of sociability and preference for social novelty in the acute and subchronic phencyclidine rat. Journal of Psychopharmacology, 2014, 28, 955-963.	2.0	18
51	Methylenetetrahydrofolate reductase (MTHFR) 677C/T polymorphism is associated with antipsychotic-induced weight gain in first-episode schizophrenia. International Journal of Neuropsychopharmacology, 2014, 17, 485-490.	1.0	19
52	Methylation at a transcription factor-binding site on the 5-HT1A receptor gene correlates with negative symptom treatment response in first episode schizophrenia. International Journal of Neuropsychopharmacology, 2014, 17, 645-649.	1.0	51
53	Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone. Human Psychopharmacology, 2014, 29, 38-45.	0.7	11
54	SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects. Therapeutic Advances in Psychopharmacology, 2014, 4, 15-21.	1.2	36

#	Article	IF	Citations
55	Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms. British Journal of Clinical Pharmacology, 2014, 77, 654-672.	1.1	42
56	Polymorphisms of serotonin neurotransmission and their effects on antipsychotic drug action. Pharmacogenomics, 2014, 15, 1599-1609.	0.6	9
57	Poster #M168 DNA METHYLATION OF THE 5-HT1A RECEPTOR GENE PROMOTER IS ASSOCIATED WITH NEGATIVE SYMPTOM RESPONSE TO ANTIPSYCHOTIC DRUG TREATMENT. Schizophrenia Research, 2014, 153, S251-S252.	1.1	0
58	Association ofFTO,LEPRandMTHFRgene polymorphisms with metabolic syndrome in schizophrenia patients receiving antipsychotics. Pharmacogenomics, 2014, 15, 477-485.	0.6	33
59	Genetic association of LMAN2L gene in schizophrenia and bipolar disorder and its interaction with ANK3 gene polymorphism. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 54, 157-162.	2.5	19
60	Association of a functional FAAH polymorphism with methamphetamine-induced symptoms and dependence in a Malaysian population. Pharmacogenomics, 2013, 14, 505-514.	0.6	19
61	Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response. Pharmacogenomics, 2013, 14, 277-288.	0.6	43
62	Genetic variation of GRIN1 confers vulnerability to methamphetamine-dependent psychosis in a Thai population. Neuroscience Letters, 2013, 551, 58-61.	1.0	20
63	The obesity risk gene FTO influences body mass in chronic schizophrenia but not initial antipsychotic drug-induced weight gain in first-episode patients. International Journal of Neuropsychopharmacology, 2013, 16, 1421-1425.	1.0	24
64	Special issue on Pharmacogenetics. Journal of Psychopharmacology, 2012, 26, 333-333.	2.0	0
65	Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response. Journal of Psychopharmacology, 2012, 26, 349-359.	2.0	60
66	Histamine and antipsychotic drug-induced weight gain. Journal of Psychopharmacology, 2012, 26, 1608-1609.	2.0	5
67	The Pharmacogenetics of Antipsychotic Treatment. Handbook of Experimental Pharmacology, 2012, , 213-239.	0.9	5
68	An association between genotypic variations and protein expression of the glial glutamate transporter 2 in the human nucleus accumbens. Neuroscience Letters, 2012, 523, 108-110.	1.0	2
69	Peripheral PDLIM5 expression in bipolar disorder and the effect of olanzapine administration. BMC Medical Genetics, 2012, 13, 91.	2.1	10
70	The Effect of Chronic Antipsychotic Drug on Hypothalamic Expression of Neural Nitric Oxide Synthase and Dopamine D2 Receptor in the Male Rat. PLoS ONE, 2012, 7, e33247.	1.1	8
71	The Pharmacogenetics of Symptom Response to Antipsychotic Drugs. Psychiatry Investigation, 2012, 9, 1.	0.7	28
72	Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review. Clinical Psychopharmacology and Neuroscience, 2012, 10, 71-77.	0.9	49

#	Article	IF	Citations
73	Hippocampal neurochemistry is involved in the behavioural effects of neonatal maternal separation and their reversal by post-weaning environmental enrichment: A magnetic resonance study. Behavioural Brain Research, 2011, 217, 122-127.	1.2	81
74	Functional consequences of twoHTR2Cpolymorphisms associated with antipsychotic-induced weight gain. Pharmacogenomics, 2011, 12, 727-734.	0.6	31
75	Learning and Memory Alterations Are Associated with Hippocampal N-acetylaspartate in a Rat Model of Depression as Measured by 1H-MRS. PLoS ONE, 2011, 6, e28686.	1.1	53
76	The Dose-Dependent Effect of Chronic Administration of Haloperidol, Risperidone, and Quetiapine on Sexual Behavior in the Male Rat. Journal of Sexual Medicine, 2011, 8, 3345-3353.	0.3	11
77	Differential regional N-acetylaspartate deficits in postmortem brain in schizophrenia, bipolar disorder and major depressive disorder. Journal of Psychiatric Research, 2011, 45, 54-59.	1.5	42
78	Receptor mechanisms of antipsychotic drug action in bipolar disorder â€“ focus on asenapine. Therapeutic Advances in Psychopharmacology, 2011, 1, 197-204.	1.2	33
79	Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes. Pharmacogenomics, 2011, 12, 1127-1136.	0.6	50
80	Metabolic side effects of antipsychotic drug treatment â€“ pharmacological mechanisms. , 2010, 125, 169-179.		327
81	Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. Journal of Affective Disorders, 2010, 123, 308-311.	2.0	50
82	Schizophreniaâ€related endophenotypes in heterozygous neuregulinâ€1 â€˜knockoutâ€™ mice. European Journal of Neuroscience, 2010, 31, 349-358.	1.2	68
83	The physical health challenges in patients with severe mental illness: cardiovascular and metabolic risks. Journal of Psychopharmacology, 2010, 24, 1-8.	2.0	11
84	Clorgyline-mediated reversal of neurological deficits in a Complexin 2 knockout mouse. Human Molecular Genetics, 2010, 19, 3402-3412.	1.4	17
85	MALE SEXUAL DYSFUNCTION IN SCHIZOPHRENIA: RELATIONSHIP WITH DRUG TREATMENT, PROLACTIN AND DRD2 GENOTYPE. Schizophrenia Research, 2010, 117, 506.	1.1	0
86	Effect of subchronic phencyclidine administration on sucrose preference and hippocampal parvalbumin immunoreactivity in the rat. Neuroscience Letters, 2010, 471, 144-147.	1.0	49
87	Effect of pretreatment with risperidone on phencyclidine-induced disruptions in object recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat. Behavioural Brain Research, 2010, 208, 132-136.	1.2	41
88	Tryptophan depletion impairs object-recognition memory in the rat: Reversal by risperidone. Behavioural Brain Research, 2010, 208, 479-483.	1.2	33
89	The effect of chronic antipsychotic drug administration on nitric oxide synthase activity and gene expression in rat penile tissues. European Neuropsychopharmacology, 2010, 20, 211-217.	0.3	9
90	Adolescent escitalopram administration modifies neurochemical alterations in the hippocampus of maternally separated rats. European Neuropsychopharmacology, 2010, 20, 875-883.	0.3	22

#	Article	IF	Citations
91	Functional Pharmacogenetics of Serotonin Receptors in Psychiatric Drug Action. Handbook of Behavioral Neuroscience, 2010, , 791-806.	0.7	2
92	Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Psychopharmacology, 2009, 207, 119-125.	1.5	76
93	Single drop behaviour in a high shear granulator. Powder Technology, 2009, 189, 357-364.	2.1	15
94	Neonatal lipopolysaccharide induces pathological changes in parvalbumin immunoreactivity in the hippocampus of the rat. Behavioural Brain Research, 2009, 205, 355-359.	1.2	57
95	Effect of acute tryptophan depletion on noradrenaline and dopamine in the rat brain. Journal of Psychopharmacology, 2009, 23, 51-55.	2.0	34
96	The neurochemistry of schizophrenia. Psychiatry (Abingdon, England), 2008, 7, 425-429.	0.2	7
97	PHARMACOGENETICS OF THE METABOLIC CONSEQUENCES OF ANTIPSYCHOTIC DRUGS. Schizophrenia Research, 2008, 102, 240.	1.1	0
98	Disturbances in social interaction occur along with pathophysiological deficits following sub-chronic phencyclidine administration in the rat. Behavioural Brain Research, 2008, 194, 230-235.	1.2	45
99	Acute tryptophan depletion does not alter central or plasma brain-derived neurotrophic factor in the rat. European Neuropsychopharmacology, 2008, 18, 317-322.	0.3	12
100	Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats. Journal of Psychopharmacology, 2008, 22, 567-571.	2.0	30
101	Influence of 5-HT_{2C}receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. British Journal of Psychiatry, 2008, 192, 424-428.	1.7	81
102	Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. Journal of Psychopharmacology, 2007, 21, 198-205.	2.0	193
103	The neuronal pathology of schizophrenia: molecules and mechanisms. Biochemical Society Transactions, 2007, 35, 433-436.	1.6	36
104	Schizophrenia, antipsychotics and metabolic disease. Journal of Psychopharmacology, 2007, 21, 355-356.	2.0	6
105	The effect of chronic antipsychotic treatment on sexual behaviour, hormones and organ size in the male rat. Journal of Psychopharmacology, 2007, 21, 428-434.	2.0	12
106	Sub-chronic phencyclidine administration increases brain-derived neurotrophic factor in the RAT hippocampus. Schizophrenia Research, 2007, 94, 371-372.	1.1	9
107	5-HT2C receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity. Brain Research, 2007, 1149, 14-17.	1.1	48
108	The impact of pharmacogenetics on the development and use of antipsychotic drugs. Drug Discovery Today, 2007, 12, 953-959.	3.2	39

#	Article	IF	Citations
109	Acute and chronic tryptophan depletion differentially regulate central 5-HT1A and 5-HT2A receptor binding in the rat. Psychopharmacology, 2007, 190, 497-506.	1.5	84
110	Deficits in parvalbumin and calbindin immunoreactive cells in the hippocampus of isolation reared rats. Journal of Neural Transmission, 2007, 114, 893-898.	1.4	134
111	Deficits of neuronal glutamatergic markers in the caudate nucleus in schizophrenia. , 2007, , 281-285.		42
112	Pharmacogenetics of schizophrenia. Expert Opinion on Pharmacotherapy, 2006, 7, 1429-1440.	0.9	15
113	The 5-HT2C receptor and antipsychoticinduced weight gain â€“ mechanisms and genetics. Journal of Psychopharmacology, 2006, 20, 15-18.	2.0	137
114	The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behavioural Brain Research, 2006, 169, 263-273.	1.2	128
115	Effect of 5-HT_{1A}Receptor Gene Polymorphism on Negative and Depressive Symptom Response to Antipsychotic Treatment of Drug-Naive Psychotic Patients. American Journal of Psychiatry, 2006, 163, 1826-1829.	4.0	100
116	Clozapine, but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus. Journal of Psychopharmacology, 2006, 20, 577-579.	2.0	28
117	Selective increases in the cytokine, TNFÎ±, in the prefrontal cortex of PCP-treated rats and human schizophrenic subjects: influence of antipsychotic drugs. Journal of Psychopharmacology, 2006, 20, 636-642.	2.0	33
118	Antioxidant capacity in postmortem brain tissues of Parkinsonâ€™s and Alzheimerâ€™s diseases. , 2006, , 39-43.		36
119	Metabolic syndrome and schizophrenia. British Journal of Psychiatry, 2006, 188, 86-86.	1.7	8
120	Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenetics and Genomics, 2005, 15, 195-200.	0.7	237
121	The neurochemistry of schizophrenia. Psychiatry (Abingdon, England), 2005, 4, 21-25.	0.2	2
122	Actions of antipsychotic drugs on pancreatic Î²-cell function: contrasting effects of clozapine and haloperidol. Journal of Psychopharmacology, 2005, 19, 597-601.	2.0	24
123	Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. European Neuropsychopharmacology, 2005, 15, 143-151.	0.3	124
124	An in vitro model of inflammatory neurodegeneration and its neuroprotection. Neuroscience Letters, 2005, 388, 39-44.	1.0	16
125	The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 1021-1028.	2.5	125
126	Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain. Schizophrenia Research, 2005, 73, 147-152.	1.1	46

#	Article	IF	Citations
127	Increased N-acetylaspartate in rat striatum following long-term administration of haloperidol. Schizophrenia Research, 2005, 75, 303-308.	1.1	51
128	Receptor Mechanisms in the treatment of Schizophrenia. Journal of Psychopharmacology, 2004, 18, 340-345.	2.0	102
129	Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. British Journal of Psychiatry, 2004, 184, 58-62.	1.7	199
130	Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat. European Journal of Pharmacology, 2004, 505, 253-254.	1.7	35
131	Calcium binding protein markers of GABA deficits in schizophrenia â€" post mortem studies and animal models. Neurotoxicity Research, 2004, 6, 57-61.	1.3	145
132	Reduced n-acetylaspartate in the temporal cortex of rats reared in isolation. Biological Psychiatry, 2004, 56, 296-299.	0.7	29
133	Region specific changes in forebrain 5-hydroxytryptamine1a and 5-hydroxytryptamine2a receptors in isolation-reared rats: an in vitro autoradiography study. Neuroscience, 2004, 123, 725-732.	1.1	80
134	The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neuroscience Letters, 2004, 372, 173-177.	1.0	122
135	Chronic haloperidol or clozapine treatment does not alter parvalbumin immunoreactivity in the rat frontal cortex or hippocampus. Neuroscience Letters, 2004, 373, 57-60.	1.0	10
136	What's new in â€¦ The neurochemistry of schizophrenia. Medicine, 2004, 32, 1-4.	0.2	0
137	N-acetylaspartate and N-Acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder: a postmortem study. Biological Psychiatry, 2003, 53, 1138-1141.	0.7	57
138	Dopamine depletion of the nucleus accumbens reverses isolation-induced deficits in prepulse inhibition in rats. Neuroscience, 2003, 119, 233-240.	1.1	77
139	Polymorphism of the Promoter Region of the Serotonin 5-HT2CReceptor Gene and Clozapine-Induced Weight Gain. American Journal of Psychiatry, 2003, 160, 677-679.	4.0	195
140	The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. Journal of Psychopharmacology, 2003, 17, 57-66.	2.0	103
141	Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia. Psychiatric Genetics, 2003, 13, 187-192.	0.6	45
142	The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study. Journal of Psychopharmacology, 2002, 16, 35-37.	2.0	51
143	Weight gain, antipsychotic drug treatment and pharmacogenomics. Pharmacogenomics, 2002, 3, 567-570.	0.6	9
144	Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biological Psychiatry, 2002, 52, 708-715.	0.7	348

#	Article	IF	Citations
145	A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophrenia Research, 2002, 55, 1-10.	1.1	416
146	Neuronal calcium-binding proteins and schizophrenia. Schizophrenia Research, 2002, 57, 27-34.	1.1	114
147	Association of antipsychotic druginduced weight gain with a 5-HT2C receptor gene polymorphism. Lancet, The, 2002, 359, 2086-2087.	6.3	392
148	The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. Journal of Psychiatric Research, 2002, 36, 317-324.	1.5	58
149	Understanding the neurotransmitter pathology of schizophrenia: selective deficits of subtypes of cortical GABAergic neurons. Journal of Neural Transmission, 2002, 109, 881-889.	1.4	80
150	The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. Journal of Neurochemistry, 2002, 81, 46-59.	2.1	98
151	Association of a polymorphism in the promoter region of theserotonin 5-HT2Creceptor gene with tardive dyskinesia in patients with schizophrenia. Molecular Psychiatry, 2002, 7, 670-671.	4.1	68
152	A selective reduction in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia patients. Chinese Medical Journal, 2002, 115, 819-23.	0.9	34
153	Neurochemical correlates of cortical GABAergic deficits in schizophrenia: selective losses of calcium binding protein immunoreactivity. Brain Research Bulletin, 2001, 55, 579-584.	1.4	136
154	Increased density of glutamate/N-methyl-d-aspartate receptors in superior temporal cortex in schizophrenia. Neuroscience Letters, 2001, 304, 9-12.	1.0	38
155	Phospholipid fatty acids and neurotoxicity in human neuroblastoma SH-SY5Y cells. Neuroscience Letters, 2001, 309, 193-196.	1.0	35
156	GABAergic neuronal subtypes in the human frontal cortex â€" development and deficits in schizophrenia. Journal of Chemical Neuroanatomy, 2001, 22, 95-100.	1.0	147
157	Antipsychotic drug use in neurodegenerative disease in the elderly: problems and potential from a pharmacological perspective. Expert Opinion on Pharmacotherapy, 2001, 2, 543-548.	0.9	5
158	Brain Neurotransmitter Deficits in Mice Transgenic for the Huntingtonâ€™s Disease Mutation. Journal of Neurochemistry, 2001, 72, 1773-1776.	2.1	84
159	Plasma homovanillic acid in untreated schizophreniaÂâ€" relationship with symptomatology and sex. Journal of Psychiatric Research, 2001, 35, 23-28.	1.5	21
160	Pharmacological Management of Neurological and Psychiatric Disorders. American Journal of Psychiatry, 2001, 158, 1539-1540.	4.0	0
161	Relationship of symptomatology, gender, and antipsychotic drug treatment with plasma homovanillic acid in schizophrenia. Acta Pharmacologica Sinica, 2001, 22, 76-80.	2.8	1
162	The new antipsychotics - some pharmacological aspects of their problems and potential. Expert Opinion on Pharmacotherapy, 2000, 1, 181-185.	0.9	4

#	Article	IF	Citations
163	Neurochemistry of Human Postmortem Brain. , 1999, , 319-346.		0
164	Dopamine receptors, antipsychotic action and schizophrenia. Journal of Psychopharmacology, 1999, 13, 202-203.	2.0	1
165	Effects of excitotoxic lesions of the rat prefrontal cortex on CREB regulation and presynaptic markers of dopamine and amino acid function in the nucleus accumbens. European Journal of Neuroscience, 1999, 11, 1265-1274.	1.2	34
166	Agonist-stimulated GTPÎ³[35S] binding to 5-HT1A receptors in human post-mortem brain. European Journal of Pharmacology, 1999, 386, 313-315.	1.7	23
167	Deficits of NMDA receptors and glutamate uptake sites in the frontal cortex in AIDS. NeuroReport, 1999, 10, 3513-3515.	0.6	29
168	Transgenic models and subcellular pathology â€" do they tell us what goes wrong in Huntington's disease?. Molecular Psychiatry, 1998, 3, 192-195.	4.1	3
169	Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease. Neuroscience Letters, 1998, 241, 53-56.	1.0	87
170	Increased density of glutamate/N-methyl-d-aspartate receptors in putamen from schizophrenic patients. Neuroscience Letters, 1998, 241, 143-146.	1.0	48
171	Developments in antipsychotic drugs â€" an update. Expert Opinion on Investigational Drugs, 1998, 7, 257-260.	1.9	2
172	Receptor mechanisms of antipsychotic drug atypicality. European Psychiatry, 1998, 13, 5s-8s.	0.1	4
173	Antipsychotic drug affinities at Î±2-adrenoceptor subtypes in post-mortem human brain. Journal of Psychopharmacology, 1998, 12, 151-154.	2.0	18
174	Pocket Handbook of Psychiatric Drug Treatment, 2nd ed.. American Journal of Psychiatry, 1998, 155, 1621-1621.	4.0	24
175	What is an atypical antipsychotic?. Journal of Psychopharmacology, 1997, 11, 195-199.	2.0	31
176	5-HT receptors, genes and antipsychotic mechanisms. Journal of Psychopharmacology, 1997, 11, 26-27.	2.0	6
177	Schizophrenia - advances in drug therapy. Expert Opinion on Investigational Drugs, 1997, 6, 857-866.	1.9	2
178	Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophrenia Research, 1997, 24, 349-355.	1.1	343
179	S.17.03 Antipsychotic drugs and neurotransmitter receptor regulation. European Neuropsychopharmacology, 1997, 7, S110-S111.	0.3	0
180	Deficits of [3H]d-aspartate binding to glutamate uptake sites in striatal and accumbens tissue in patients with schizophrenia. Neuroscience Letters, 1997, 232, 13-16.	1.0	33

#	Article	IF	Citations
181	Neurotransmitter receptors, genes and schizophrenia. European Neuropsychopharmacology, 1996, 6, S4-29-S4-30.	0.3	0
182	Imidazoline binding sites in Huntington's and Parkinson's disease putamen. European Journal of Pharmacology, 1996, 301, R19-R21.	1.7	43
183	An improved model for examining delayed excitotoxic neurodegeneration in isolated chick retina. Neuroscience Letters, 1996, 219, 65-67.	1.0	1
184	The Importance of Dopamine D4 Receptors in the Action and Development of Antipsychotic Agents. Drugs, 1996, 51, 7-11.	4.9	42
185	Dopamine deficits in the brain. NeuroReport, 1996, 7, 910-912.	0.6	117
186	5-Hydroxytryptamine deficits in the caudate nucleus in AIDS. Aids, 1996, 10, 1303-1304.	1.0	7
187	Dopamine receptors and schizophrenia. Biochemical Society Transactions, 1996, 24, 202-205.	1.6	9
188	Dopamine D4 receptors in schizophrenia?. Journal of Neurochemistry, 1996, 66, 881-3.	2.1	10
189	Dopamine receptors and schizophrenia. Biochemical Society Transactions, 1996, 24, 202-5.	1.6	3
190	Muscarinic M1 receptors in schizophrenia. Molecular Psychiatry, 1996, 1, 364-6.	4.1	2
191	Neurotransmitter Systems in Schizophrenia. International Review of Neurobiology, 1995, 38, 305-339.	0.9	15
192	An investigation of the activities of 3-hydroxykynureninase and kynurenine aminotransferase in the brain in Huntington's disease. Journal of Neural Transmission, 1995, 102, 67-73.	1.4	15
193	Consensus on minimal criteria of clinical and neuropathological diagnosis of schizophrenia and affective disorders for post mortem research. Journal of Neural Transmission, 1995, 102, 255-264.	1.4	16
194	Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. Journal of Psychiatric Research, 1995, 29, 227-232.	1.5	132
195	Clozapine-induced hypersalivation and the alpha2 adrenoceptor. British Journal of Psychiatry, 1995, 167, 412-412.	1.7	86
196	New Approaches to the Drug Treatment of Schizophrenia. Advances in Pharmacology, 1995, 32, 461-503.	1.2	23
197	Characterization of [3H]GR 113808 binding to 5-HT4 receptors in brain tissues from patients with neurodegenerative disorders. Behavioural Brain Research, 1995, 73, 249-252.	1.2	60
198	Absence of detectable striatal dopamine D4 receptors in drug-treated schizophrenia. European Journal of Pharmacology, 1995, 281, R5-R6.	1.7	73

#	Article	IF	Citations
199	Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia. Neuroscience Letters, 1995, 187, 9-12.	1.0	68
200	5â€Hydroxytryptamine (5â€HT)₄ receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. British Journal of Pharmacology, 1995, 114, 993-998.	2.7	179
201	Increased Concentrations of the Neurotoxin 3â€Hydroxykynurenine in the Frontal Cortex of HIVâ€1â€Positive Patients. Journal of Neurochemistry, 1995, 64, 932-935.	2.1	81
202	Neocortical neurotransmitter markers in Huntington's disease. Journal of Neural Transmission, 1994, 98, 197-207.	1.4	8
203	Differential regulation of cardiac Î±- and Î²-adrenoceptors by the sympathetic nervous system. Autonomic and Autacoid Pharmacology, 1994, 14, 29-36.	0.7	3
204	Deficit of [3H]L-689,560 binding to the glycine site of the glutamate/NMDA receptor in the brain in Huntington's disease. Journal of the Neurological Sciences, 1994, 125, 46-49.	0.3	12
205	Glutamate in Huntington's disease. Lancet, The, 1994, 344, 189-190.	6.3	12
206	Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia. Acta Psychiatrica Scandinavica, 1994, 89, 36-40.	2.2	26
207	Arachidonic Acid: A Common Link in the Biology of Schizophrenia?. Archives of General Psychiatry, 1994, 51, 665.	13.8	61
208	Are Striatal Dopamine D₄ Receptors Increased in Schizophrenia?. Journal of Neurochemistry, 1994, 63, 1576-1577.	2.1	87
209	Hippocampal tin, aluminum and zinc in Alzheimer's disease. BioMetals, 1993, 6, 149-54.	1.8	112
210	D-aspartate binding to the glutamate uptake site in human brain tissue ? effects of leucotomy. Journal of Neural Transmission, 1993, 94, 147-152.	1.4	6
211	Hippocampal benzodiazepine receptors in schizophrenia. Journal of Neural Transmission, 1993, 93, 151-155.	1.4	22
212	Glutamate stimulates dopamine release from cortical and limbic rat brain in vitro. European Journal of Pharmacology, 1993, 242, 183-187.	1.7	19
213	Free radical damage in Down's syndrome brain. Biochemical Society Transactions, 1993, 21, 221S-221S.	1.6	17
214	Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. International Clinical Psychopharmacology, 1993, 8, 151-154.	0.9	92
215	Cholinergic Basis for Alzheimer Therapy. American Journal of Psychiatry, 1993, 150, 1265-1265.	4.0	0
216	Neurochemical-clinical correlates in Huntington's disease--applications of brain banking techniques. Journal of Neural Transmission Supplementum, 1993, 39, 207-14.	0.5	7

#	Article	IF	Citations
217	The ratio of plasma phenylalanine to other large neutral amino acids is not a risk factor for tardive dyskinesia. Journal of Psychopharmacology, 1992, 6, 278-280.	2.0	1
218	An evaluation of structural and functional prefrontal deficits in schizophrenia: MRI and neuropsychological measures. Psychiatry Research - Neuroimaging, 1992, 45, 123-137.	0.9	93
219	Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. Neuroscience Letters, 1992, 144, 199-201.	1.0	135
220	Pre-frontal structural and functional deficits associated with individual differences in schizotypal personality. Schizophrenia Research, 1992, 7, 237-247.	1.1	131
221	Neurochemical abnormalities in huntington's disease: Neurotoxic mechanisms and neurotransmitter changes. Journal of the Neurological Sciences, 1992, 113, 230-231.	0.3	4
222	Developments in the drug treatment of schizophrenia. Trends in Pharmacological Sciences, 1992, 13, 116-121.	4.0	145
223	Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue. European Journal of Pharmacology, 1992, 221, 397-398.	1.7	59
224	Monoamine neurotransmitters and their metabolites in brain regions in alzheimer's disease: A postmortem study. Cellular and Molecular Neurobiology, 1992, 12, 581-587.	1.7	97
225	Studies on brain monoamine oxidase: a laboratory investigation in neurochemistry for first-year undergraduates. Biochemical Education, 1992, 20, 55-56.	0.1	1
226	Dopamine receptor abnormalities in the striatum and pallidum in tardive dyskinesia: a post mortem study. Journal of Neural Transmission, 1992, 87, 225-230.	1.4	17
227	[3H]Ditolylguanidine binding to human brain ĭf sites is diminished after haloperidol treatment. European Journal of Pharmacology, 1991, 194, 235-236.	1.7	27
228	Determination of 3-hydroxykynurenine in human brain and plasma by high-performance liquid chromatography with electrochemical detection. Biomedical Applications, 1991, 565, 436-440.	1.7	52
229	Neuroanatomical Correlates of Skin Conductance Orienting in Normal Humans: A Magnetic Resonance Imaging Study. Psychophysiology, 1991, 28, 548-558.	1.2	89
230	Electrochemical detection of human brain transmitter amino acids by high-performance liquid chromatography of stable O-phthalaldehyde-sulphite derivatives. Journal of Neural Transmission, 1991, 86, 151-157.	1.4	43
231	[3H]Nipecotic Acid Binding to ?-Aminobutyric Acid Uptake Sites in Postmortem Human Brain. Journal of Neurochemistry, 1990, 55, 165-168.	2.1	12
232	Pallidal GABA and chorea in Huntington's disease. Journal of Neural Transmission, 1990, 81, 241-246.	1.4	12
233	Structural and Functional Characteristics of the Corpus Callosum in Schizophrenics, Psychiatric Controls, and Normal Controls. Archives of General Psychiatry, 1990, 47, 1060.	13.8	104
234	Dementia in Huntington's disease is associated with neurochemical deficits in the caudate nucleus, not the cerebral cortex. Neuroscience Letters, 1990, 113, 95-100.	1.0	32

#	Article	IF	Citations
235	No deficit of pallidal D2 dopamine receptors in Huntington's disease. Journal of the Neurological Sciences, 1990, 100, 238.	0.3	1
236	Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia. Biological Psychiatry, 1990, 27, 1038-1044.	0.7	198
237	Dopamine D2 -Receptors in Post-mortem Human Brains from Schizophrenic Patients. , 1990, , 507-513.		0
238	Alzheimer-like changes of cortical amino acid transmitters in elderly Downâ€™s syndrome. Key Topics in Brain Research, 1990, , 283-288.	0.2	0
239	Recommended minimum data to be collected in research studies on Alzheimer's disease. The MRC (UK) Alzheimer's Disease Workshop Steering Committee.. Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 693-700.	0.9	55
240	[3H] GBR 12935 binding to the dopamine uptake site in post-mortem brain tissue in schizophrenia. Journal of Neural Transmission, 1989, 77, 227-230.	1.4	31
241			

#	Article	IF	Citations
253	Beyond the Dopamine Hypothesis. British Journal of Psychiatry, 1989, 155, 305-316.	1.7	156
254	Dopamine Receptors: Receptor Biochemistry and Methodology, vol. 8. American Journal of Psychiatry, 1989, 146, 672-673.	4.0	0
255	Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. Journal of Neural Transmission, 1988, 74, 199-205.	1.4	685
256	Brain Quinolinic Acid in Huntington's Disease. Journal of Neurochemistry, 1988, 50, 1959-1968.	2.1	105
257	Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease. Neuropharmacology, 1988, 27, 717-719.	2.0	27
258	GLUTAMATE DEHYDROGENASE ACTIVITY IN AMYOTROPHIC LATERAL SCLEROSIS. Lancet, The, 1988, 332, 914.	6.3	0
259	ASYMMETRICAL LOSS OF GLUTAMATE RECEPTOR SUBTYPE IN LEFT HIPPOCAMPUS IN SCHIZOPHRENIA. Lancet, The, 1988, 331, 583-584.	6.3	166
260	Amino acid neurotransmitter deficits in adult Down's syndrome brain tissue. Neuroscience Letters, 1988, 94, 224-227.	1.0	54
261	Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea. Neuroscience, 1988, 25, 419-438.	1.1	117
262	Post-mortem neurochemistry of schizophrenia. Psychological Medicine, 1988, 18, 793-797.	2.7	18
263	Status of the dopaminergic system in post-mortem brain in schizophrenia. Psychopharmacology Bulletin, 1988, 24, 345-7.	0.0	14
264	Human cytomegalovirus DNA in the temporal cortex of a schizophrenic patient. European Archives of Psychiatry and Neurological Sciences, 1988, 238, 110-113.	0.9	22
265	Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue.. Journal of Neurology, Neurosurgery and Psychiatry, 1987, 50, 775-778.	0.9	104
266	NEURONAL DEGENERATION IN LOCUS CERULEUS AND CORTICAL CORRELATES OF ALZHEIMER DISEASE. Alzheimer Disease and Associated Disorders, 1987, 1, 256-262.	0.6	145
267	Age and Histopathologic Heterogeneity in Alzheimer's Disease. Archives of General Psychiatry, 1987, 44, 412.	13.8	87
268	Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain. Neuroscience Letters, 1987, 78, 233-238.	1.0	78
269	A correlative study on hippocampal cation shifts and amino acids and clinico-pathological data in Alzheimer's disease. Neurobiology of Aging, 1987, 8, 487-494.	1.5	15
270	Maintenance of cortical somatostatin and monoamine levels in the rat does not require intact cholinergic innervation. Brain Research, 1987, 406, 326-329.	1.1	13

#	Article	IF	Citations
271	Neuropathology of Huntington's disease. Trends in Neurosciences, 1987, 10, 404.	4.2	2
272	Region-specific loss of glutamate innervation in Alzheimer's disease. Neuroscience Letters, 1987, 73, 77-80.	1.0	146
273	A disorder of cortical GABAergic innervation in Alzheimer's disease. Neuroscience Letters, 1987, 73, 192-196.	1.0	104
274	DOPAMINE RECEPTOR ASYMMETRY IN SCHIZOPHRENIA. Lancet, The, 1987, 329, 979.	6.3	41
275	HPLC analysis of somatostatin related peptides in putamen of Huntington's Disease patients. Journal of Neural Transmission, 1987, 69, 153-160.	1.4	4
276	Human brain dopamine receptors in children and aging adults. Synapse, 1987, 1, 399-404.	0.6	396
277	Decreased brown adipose tissue thermogenic activity following a reduction in brain serotonin by intraventricular p-chlorophenylalanine. Bioscience Reports, 1987, 7, 121-127.	1.1	19
278	Postmortem Neurochemical Studies in Schizophrenia. , 1987, , 236-240.		9
279	Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology, 1987, 1, 5-15.	2.8	289
280	Reduced high-affinity glutamate uptake sites in the brains of patients with Huntington's disease. Neuroscience Letters, 1986, 67, 198-202.	1.0	64
281	LITHIUM PROPHYLAXIS INHIBITS CHOLINE TRANSPORT IN POST-MORTEM BRAIN. Lancet, The, 1986, 328, 458.	6.3	8
282	Brain serotonin receptors in Huntington's disease. Neurochemistry International, 1986, 9, 431-435.	1.9	14
283	Monoclonal antibodies raised against a subsequence of senile plaque core protein react with plaque cores, plaque periphery and cerebrovascular amyloid in Alzheimer's disease. Neuroscience Letters, 1986, 68, 252-256.	1.0	146
284	Regional distribution of a novel peptide (P7 of 1B236) immunoreactivity in the human central nervous system. Neuroscience Letters, 1986, 67, 58-62.	1.0	2
285	Dopamine D2 receptor density remains constant in treated Parkinson's disease. Annals of Neurology, 1986, 19, 487-492.	2.8	96
286	Striatal dopamine and homovanillic acid in Huntington's Disease. Journal of Neural Transmission, 1986, 65, 151-155.	1.4	29
287	Subcellular Pathology of Human Neurodegenerative Disorders: Alzheimerâ€Type Dementia and Huntington's Disease. Journal of Neurochemistry, 1986, 47, 882-889.	2.1	21
288	Amygdala Dopamine Asymmetry in Schizophrenia: Neurochemical Evidence for a Left Temporal Lobe Dysfunction. , 1986, , 285-291.		2

#	Article	IF	Citations
289	Search for Cytomegalovirus in Postmortem Brain Tissue from Patients with HuntingtonÊ¼s Chorea and other Psychiatric Disease by Molecular Hybridization Using Cloned DNA. Journal of Neuropathology and Experimental Neurology, 1985, 44, 176-184.	0.9	20
290	Ascending Systems in Alzheimerï¿½s Disease. Interdisciplinary Topics in Gerontology and Geriatrics, 1985, 19, 198-212.	2.6	1
291	Recombinant DNA studies on stored necropsy brain samples from patients with Huntington's chorea.. Journal of Clinical Pathology, 1985, 38, 1093-1095.	1.0	2
292	ALZHEIMER-LIKE BRAIN MONOAMINE DEFICITS IN ADULTS WITH DOWN'S SYNDROME. Lancet, The, 1985, 326, 1368-1369.	6.3	25
293	Acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the adrenal glands as well as the brain in the marmoset. Neuroscience Letters, 1985, 58, 123-126.	1.0	19
294	Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and Î³-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases. Journal of the Neurological Sciences, 1985, 67, 161-171.	0.3	122
295	[3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. European Journal of Pharmacology, 1985, 114, 235-237.	1.7	118
296	Neurochemical Studies in Human Postmortem Brain Tissue. , 1985, , 477-496.		1
297	Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. Reduced cortical and striatal concentrations. JAMA - Journal of the American Medical Association, 1985, 254, 3067-3069.	3.8	84
298	Dopamine Function and Neuroleptics in Schizophrenia â€" Post-Mortem Studies of Human Brain Tissue. , 1985, , 209-213.		0
299	Receptors, Neuroleptics and Dopamine Concentrations in Schizophrenia â€" Postmortem Studies of Human Brain Tissue. , 1985, , 29-34.		2
300	Brain Biochemistry in Schizophrenia: An Assessment. , 1985, , 35-43.		4
301	Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. Reduced cortical and striatal concentrations. JAMA - Journal of the American Medical Association, 1985, 254, 3067-9.	3.8	26
302	Early and late onset types of Alzheimer's disease. BMJ: British Medical Journal, 1984, 288, 1612-1612.	2.4	0
303	Neurochemical characteristics of early and late onset types of Alzheimer's disease.. BMJ: British Medical Journal, 1984, 288, 961-964.	2.4	375
304	Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science, 1984, 225, 728-731.	6.0	345
305	Decreased Proline Endopeptidase Activity in the Basal Ganglia in Huntington's Disease. Journal of Neurochemistry, 1984, 43, 878-880.	2.1	11
306	TETRAHYDROBIOPTERIN METABOLISM IN DEPRESSION. Lancet, The, 1984, 324, 163.	6.3	40

#	Article	IF	Citations
307	Reduced binding of [3H]ketanserin to cortical 5-HT2 receptors in senile dementia of the Alzheimer type. Neuroscience Letters, 1984, 44, 47-51.	1.0	138
308	The pharmacology of Parkinson's disease: l-dopa and beyond. Trends in Pharmacological Sciences, 1984, 5, 25-27.	4.0	6
309	Noradrenaline and schizophrenia. Trends in Pharmacological Sciences, 1984, 5, 138.	4.0	0
310	Banbury Report 15, Biological Aspects of Alzheimer's Disease. Trends in Pharmacological Sciences, 1984, 5, 246.	4.0	12
311	NEUROCHEMICAL ASYMMETRY OF THE LIMBIC SYSTEM IN SCHIZOPHRENIA. Clinical Neuropharmacology, 1984, 7, S496.	0.2	1
312	Phenylethylamine and Schizophrenia â€" Clinical and Pharmacological Results. , 1984, , 515-523.		1
313	Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature, 1983, 305, 527-529.	13.7	400
314	Neuropharmacology: Pathophysiology of schizophrenia â€" causal role for dopamine or noradrenaline?. Nature, 1983, 305, 577-577.	13.7	17
315	Loss of pigmented dopamine-Î²-hydroxylase positive cells from locus coeruleus in senile dementia of alzheimer's type. Neuroscience Letters, 1983, 39, 95-100.	1.0	270
316	Neurotensin in the adrenal medulla. Neuroscience Letters, 1983, 35, 155-160.	1.0	46
317	SEROTONIN RECEPTORS IN SUICIDE VICTIMS. Lancet, The, 1983, 322, 977.	6.3	7
318	Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients. Psychiatry Research, 1983, 8, 243-250.	1.7	55
319	Chronic clozapine treatment of rats down-regulates cortical 5-HT2 receptors. European Journal of Pharmacology, 1983, 89, 325-326.	1.7	69
320	Tranylcypromine Isomers in Parkinsonï¿½s Disease. Modern Problems of Pharmacopsychiatry, 1983, 19, 154-161.	2.5	3
321	Assessment of MAO Inhibitors Using Postmortem Human Brain Tissue: Biochemical and Therapeutic Implications. Modern Problems of Pharmacopsychiatry, 1983, 19, 255-259.	2.5	1
322	Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action. Journal of Neural Transmission Supplementum, 1983, 18, 273-7.	0.5	21
323	THIORIDAZINE IS NOT SPECIFIC FOR LIMBIC DOPAMINE RECEPTORS. Lancet, The, 1982, 320, 499-500.	6.3	27
324	Parkinson's disease putamen: Normal concentration of synaptic membrane marker antigens. Journal of Neural Transmission, 1982, 54, 171-179.	1.4	8

#	Article	IF	Citations
325	Phenylethylamine and phenylacetic acid in CSF of schizophrenics and healthy controls. Archiv Fur Psychiatrie Und Nervenkrankheiten, 1982, 232, 463-471.	0.6	25
326	DOPAMINE RECEPTORS IN POST-MORTEM SCHIZOPHRENIC BRAINS. Lancet, The, 1981, 317, 1261.	6.3	1
327	Tranylcypromine Isomers in the Treatment of Parkinsonâ€™s Disease. International Pharmacopsychiatry, 1981, 16, 30-33.	0.4	7
328	The effects of lisuride and some other dopaminergic agonists on receptor binding in human brain. Journal of Neural Transmission, 1981, 51, 107-111.	1.4	9
329	Determination of a wide range of urinary amine metabolites using a simple high-performance liquid chromatographic technique. Biomedical Applications, 1981, 225, 179-184.	1.7	12
330	Tranylcypromine isomers and Parkinson's disease: new aspects of an old drug. Journal of the Royal Society of Medicine, 1981, 74, 649-52.	1.1	0
331	Dopamine receptors and schizophrenia: the neuroleptic drug problem. Neuropharmacology, 1981, 20, 1319-20.	2.0	32
332	TRACE AMINE DEFICIT IN DEPRESSIVE ILLNESS: THE PHENYLALANINE CONNEXION. Acta Psychiatrica Scandinavica, 1980, 61, 29-39.	2.2	19
333	The Determination and Distribution of2-Phenylethylamine in Sheep Brain. Journal of Neurochemistry, 1980, 34, 1123-1125.	2.1	28
334	Deprenyl is a selective inhibitor of brain MAOâ€B in the longâ€term treatment of Parkinsons's disease.. British Journal of Clinical Pharmacology, 1980, 9, 98-99.	1.1	16
335	Effects of tranylcypromine stereoisomers on monamine oxidation in man.. British Journal of Clinical Pharmacology, 1980, 9, 521-523.	1.1	37
336	DOPAMINE RECEPTORS AND SCHIZOPHRENIA: DRUG EFFECT OR ILLNESS. Lancet, The, 1980, 316, 1251.	6.3	36
337	Dopamine Metabolism in Human Brain: Effects of Monoamine Oxidase Inhibition in vitro by (â€”)Deprenyl and (+) and (â€”)Tranylcypromine. , 1980, , 173-178.		10
338	2-Phenylethylamine and Amphetamine in Human Brain: Effects of l-Deprenyl in Parkinson's Disease. Biochemical Society Transactions, 1979, 7, 143-145.	1.6	20
339	Deficient production of tyramine and octopamine in cases of depression. Nature, 1979, 278, 357-358.	13.7	96
340	Phenylethylamine â€” a role in mental illness?. Trends in Neurosciences, 1979, 2, 265-268.	4.2	19
341	Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ?cheese effect?. Psychopharmacology, 1978, 57, 33-38.	1.5	247
342	Gas chromatographic detection of N-methyl-2-phenylethylamine: a new component of human urine. Biomedical Applications, 1978, 145, 137-140.	1.7	9

#	Article	IF	Citations
343	Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration. Journal of Neural Transmission, 1978, 43, 271-277.	1.4	133
344	Deprenyl is metabolized to methamphetamine and amphetamine in man.. British Journal of Clinical Pharmacology, 1978, 6, 542-544.	1.1	270
345	The urinary excretion of 2-phenylethylamine in phenylketonuria. Clinica Chimica Acta, 1978, 83, 33-39.	0.5	20
346	The effect of urinary pH and flow rate on monoamine output. Clinica Chimica Acta, 1978, 84, 225-231.	0.5	7
347	Raised cerebrospinal fluid phenylacetic acid concentration: preliminary support for the phenylethylamine hypothesis of schizophrenia?. Communications in Psychopharmacology, 1978, 2, 199-202.	0.3	14
348	DOES PHENYLETHYLAMINE CAUSE SCHIZOPHRENIA?. Lancet, The, 1976, 307, 70-71.	6.3	120
349	A method for the estimation of 2-phenylethylamine in human urine by gas chromatography. Clinica Chimica Acta, 1976, 70, 213-217.	0.5	16
350	Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. Journal of Psychopharmacology, 0, , .	2.0	5
351	Brain derived neurotrophic factor (BDNF) methylation in patients with impaired glucose regulation: implications progression to type 2 diabetes mellitus (T2DM). Endocrine Abstracts, 0, , .	0.0	0
352	CACNA1C genotype does influence CACNA1C methylation and the association with cortisol release/potential mental health resilience. Endocrine Abstracts, 0, , .	0.0	0